ATS 2026 at a glance
ATS 2026 in Orlando highlights emerging developments in respiratory medicine, from biomarker-defined COPD biologics and antifibrotic therapies to bronchiectasis treatment, pulmonary arterial hypertension (PAH) and artificial intelligence.
The strategic focus extends beyond individual diseases to treatment differentiation, patient segmentation, emerging therapeutic approaches and AI applications in respiratory care.
📅 Build your schedule around the topics that matter most.
📥 Download the ATS 2026_Preview_by_LucidQuest
ATS 2026: Key Developments in Respiratory Disease Treatment
COPD Biologics and Precision Treatment
Itepekimab, tozorakimab, and GSK’s eosinophilic COPD focus will test biomarker-defined biologic positioning beyond inhaled escalation.
Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) Treatment
Nerandomilast, Bristol Myers Squibb fibrosis programming, BMS-986278 context, and treprostinil data may shift differentiation toward sequencing, tolerability, and burden.
Bronchiectasis Treatment and Emerging Therapies
BRINSUPRI® / brensocatib, diagnostic-gap sessions, home high-flow therapy, and MAC / NTM data will pressure future NCFB care pathways.
Pulmonary Arterial Hypertension (PAH) Treatment Sequencing
Sotatercept data across CTD-associated PAH, early access, double-background therapy, and comorbid populations may clarify broader sequencing potential.
Respiratory Medicine Competitor and Industry Developments
Regeneron and Sanofi: IL-33 Blockade in COPD
Itepekimab AERIFY-1/2 data will provide a direct readout for IL-33 blockade in former-smoker COPD.
AstraZeneca: COPD Inflammation and IL-33/ST2 Biology
Tozorakimab and IL-33 / ST2 biology sessions will support COPD inflammation and mucus-dysfunction positioning.
Insmed: Bronchiectasis Treatment and BRINSUPRI
BRINSUPRI® / brensocatib programming suggests bronchiectasis is becoming a launch-ready market shaped by diagnosis and exacerbation-risk stratification.
Boehringer Ingelheim and BMS: Pulmonary Fibrosis Treatment
Fibrosis education and nerandomilast programming will keep IPF / PPF differentiation focused on subgroup utility and patient burden.
Artificial Intelligence and Machine Learning at ATS 2026
AI in Respiratory Medicine and Clinical Workflows
AI-based imaging, COPD prediction, PAH recognition, lung cancer screening, ILD phenotyping, and remote monitoring are moving closer to clinical decision points.
AI-Driven Trial Enrichment and Respiratory Disease Prediction
Imaging-derived severity, progression markers, and phenotype classification may influence earlier detection, specialist referral, and study design.
What to Watch After ATS 2026
- IL-33 Validation in COPD: Whether AERIFY-1/2 data demonstrate enough COPD efficacy to support IL-33 blockade beyond inhaled escalation pathways.
- Bronchiectasis Treatment Adoption: Whether BRINSUPRI® / brensocatib and Insmed’s programming shift NCFB management toward DPP1 inhibition and earlier diagnosis.
- Alpha-1 Antitrypsin Deficiency (AATD) Treatment Innovation: Whether restoration and genetic approaches show enough clinical relevance to challenge plasma-derived augmentation models.
Download LucidQuest’s ATS 2026 Preview Report
Download our ATS 2026 preview report for deeper analysis of COPD biologics, pulmonary fibrosis treatments, bronchiectasis therapies, PAH treatment sequencing, competitor positioning and AI applications in respiratory medicine.
📅 Build your schedule around the sessions that matter most.
📥 Download the ATS 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
